Market Trends Novartis receives third FDA approval for oral Fabhalta treatment for kidney disease C3GBy admin8996erT0allMarch 21, 2025 TBE/iStock Editorial via Getty Images Novartis (NYSE:NVS) Thursday said that oral Fabhalta (iptacopan) has received U.S. Food and Drug Administration…
Market Trends Merck releases positive phase 3 data on daily oral HIV drug (MRK:NYSE)By admin8996erT0allMarch 12, 2025 Erik S. Lesser/Getty Images NewsMerck (NYSE:MRK) said that data from a pair of late-stage trials showed that an oral, two-drug…
